Literature DB >> 10453972

Vinorelbine tartrate-induced pulmonary edema confirmed on rechallenge.

C E Cattan1, K C Oberg.   

Abstract

A 67-year-old woman with metastatic breast cancer experienced sudden and profound pulmonary edema within 45 minutes after completion of intravenous administration of vinorelbine tartrate on two occasions. Both times the drug was discontinued and the patient was treated aggressively with oxygen, intravenous furosemide, and a vasodilator. The patient suffered no lasting medical complications due to the reaction. Until clear documentation and the mechanism for occurrence of this reaction are known, patients receiving vinorelbine should be monitored closely, particularly in the first few hours after intravenous administration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10453972     DOI: 10.1592/phco.19.11.992.31580

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  Soluble adenylyl cyclase-dependent microtubule disassembly reveals a novel mechanism of endothelial cell retraction.

Authors:  Nutan Prasain; Mikhail Alexeyev; Ron Balczon; Troy Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-04-24       Impact factor: 5.464

Review 2.  Emerging themes of cAMP regulation of the pulmonary endothelial barrier.

Authors:  Sarah L Sayner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-02-18       Impact factor: 5.464

3.  The leading role of microtubules in endothelial barrier dysfunction: disassembly of peripheral microtubules leaves behind the cytoskeletal reorganization.

Authors:  Irina B Alieva; Evgeny A Zemskov; Ksenija M Smurova; Irina N Kaverina; Alexander D Verin
Journal:  J Cell Biochem       Date:  2013-10       Impact factor: 4.429

Review 4.  The actin cytoskeleton in endothelial cell phenotypes.

Authors:  Nutan Prasain; Troy Stevens
Journal:  Microvasc Res       Date:  2008-10-26       Impact factor: 3.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.